Sangamo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Sangamo Therapeutics Inc SGMO.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of seven analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -16 cents to -10 cents per share.

• Revenue rose 1,238.3% to $6.44 million from a year ago; analysts expected $7.42 million.

• Sangamo Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.

• Sangamo Therapeutics Inc shares had risen by 6.8% this quarter and lost 31.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 190.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $3.50

This summary was machine generated from LSEG data May 12 at 10:47 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)